Seattle-based Dendreon, a publicly held biopharmaceuticals firm, announced this morning that it has received a commitment for $130M in equity funding from Azimuth Opportunity, Ltd. According to Dendreon, it is not obligated to use the equity financing facility and is free to enter into other equity and debt financing transactions. The firm is developing therapeutics for the treatment of cancer.